AU
CA
NZ
UK
US
IND
Kalkine has a fully transformed New Avatar.
Last update at 2024-10-09T19:00:43.705845Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Should You Invest on Alimera Sciences, Inc. (ALIM) Right Now?
Fri 09 Aug 24, 11:43 AMVelan Capital Investment Management LP Boosts Stake in Alimera Sciences Inc
Thu 03 Aug 23, 11:03 PMInvestor Summit Group Provides Update on Upcoming Q4 Virtual Summit
Fri 05 Nov 21, 10:05 PM47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th
Wed 03 Jun 20, 01:00 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -18.07900M | -3.93400M | -5.40700M | -10.22700M | -16.27700M |
| Minority interest | - | - | - | - | - |
| Net income | -18.10700M | -4.37200M | -5.33900M | -10.44300M | -16.38300M |
| Selling general administrative | 12.87M | 12.77M | 11.65M | 13.95M | 14.53M |
| Selling and marketing expenses | 25.99M | 23.07M | 20.38M | 25.00M | 23.52M |
| Gross profit | 46.15M | 52.00M | 43.88M | 47.32M | 42.29M |
| Reconciled depreciation | 2.71M | 2.58M | 2.68M | 2.64M | 2.65M |
| Ebit | -11.64000M | -0.20100M | -0.50100M | -5.27400M | -9.67000M |
| Ebitda | -8.93400M | 2.38M | 2.17M | -2.63300M | -7.02500M |
| Depreciation and amortization | 2.71M | 2.58M | 2.68M | 2.64M | 2.65M |
| Non operating income net other | - | - | 0.47M | -0.08400M | -1.83100M |
| Operating income | -11.64000M | -0.20100M | -0.50100M | -5.27400M | -9.67000M |
| Other operating expenses | 65.77M | 59.23M | 51.32M | 59.22M | 56.64M |
| Interest expense | 5.88M | 5.41M | 5.38M | 4.87M | 4.78M |
| Tax provision | 0.03M | 0.44M | -0.06800M | 0.22M | 0.11M |
| Interest income | - | - | - | 4.95M | 4.84M |
| Net interest income | -5.88100M | -5.41300M | -5.38000M | -4.86900M | -4.77500M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.03M | 0.44M | -0.06800M | 0.22M | 0.11M |
| Total revenue | 54.13M | 59.03M | 50.82M | 53.94M | 46.97M |
| Total operating expenses | 57.79M | 52.20M | 44.38M | 52.59M | 51.96M |
| Cost of revenue | 7.98M | 7.03M | 6.94M | 6.63M | 4.68M |
| Total other income expense net | -6.43900M | -3.73300M | -4.90600M | -4.95300M | -1.83100M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -18.10700M | -4.37200M | -5.33900M | -10.44300M | -16.38200M |
| Net income applicable to common shares | - | -4.37200M | -5.33900M | -10.44300M | 21.95M |
| Preferred stock and other adjustments | - | - | - | - | -38.33000M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 153.52M | 42.60M | 58.52M | 50.85M | 50.31M |
| Intangible assets | 97.36M | 8.96M | 10.90M | 12.84M | 14.78M |
| Earning assets | - | - | - | - | - |
| Other current assets | 3.91M | 2.89M | 3.81M | 3.72M | 2.56M |
| Total liab | 107.35M | 63.45M | 61.12M | 58.83M | 54.75M |
| Total stockholder equity | 46.17M | -20.84800M | -2.60500M | -7.97800M | -4.44500M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 12.83M | 4.00M | 3.40M | 3.20M | 4.72M |
| Common stock | 0.52M | 0.07M | 0.07M | 0.06M | 0.05M |
| Capital stock | 0.52M | 19.30M | 19.30M | 19.28M | 30.39M |
| Retained earnings | -418.49000M | -415.38800M | -397.28100M | -392.90900M | -387.57000M |
| Other liab | - | - | 2.72M | 3.56M | 3.12M |
| Good will | - | - | - | 12.84M | 14.78M |
| Other assets | - | - | 0.97M | 1.47M | 0.73M |
| Cash | 12.09M | 5.27M | 16.51M | 11.21M | 9.43M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 21.91M | 39.73M | 12.59M | 12.35M | 12.05M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | 55.31M | 39.05M | 27.06M | 33.40M | 29.58M |
| Short term debt | 0.83M | 25.65M | 0.49M | 1.69M | 0.26M |
| Short long term debt | - | 25.31M | - | 1.48M | - |
| Short long term debt total | 67.40M | 44.33M | 43.57M | 44.61M | 39.01M |
| Other stockholder equity | 458.57M | 378.24M | 377.23M | 366.20M | 353.82M |
| Property plant equipment | - | - | 4.49M | 1.64M | 2.05M |
| Total current assets | 52.42M | 29.41M | 42.16M | 34.91M | 32.74M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | -29.11100M | -39.52900M | -49.47800M |
| Short term investments | - | - | - | - | - |
| Net receivables | 34.55M | 19.61M | 19.13M | 17.20M | 19.33M |
| Long term debt | 64.49M | 18.68M | 43.08M | 42.41M | 38.66M |
| Inventory | 1.88M | 1.60M | 2.68M | 2.75M | 1.39M |
| Accounts payable | 8.25M | 10.09M | 8.71M | 7.46M | 7.08M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 1.69M | -2.99500M | -1.84900M | -0.55300M | -1.09300M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 0.06M | 0.05M |
| Preferred stock total equity | - | - | - | 19.23M | 30.34M |
| Retained earnings total equity | - | - | - | -392.90900M | -387.57000M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.05M | 0.18M | 0.83M | 0.72M | 2.05M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 101.10M | 13.19M | 16.36M | 15.95M | 17.56M |
| Capital lease obligations | 0.83M | 1.10M | 0.49M | 0.72M | 0.82M |
| Long term debt total | - | - | - | 42.41M | 38.66M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.25500M | -0.62100M | -0.62000M | -0.17400M | -0.17500M |
| Change to liabilities | - | 1.49M | -2.07900M | 1.81M | 2.55M |
| Total cashflows from investing activities | - | -0.62100M | -0.62000M | -0.17400M | -0.17500M |
| Net borrowings | - | -0.22100M | 3.83M | 0.27M | 0.99M |
| Total cash from financing activities | -0.30200M | 9.82M | 3.88M | 0.87M | 0.95M |
| Change to operating activities | - | -0.60900M | -2.86800M | 0.20M | 2.12M |
| Net income | -18.10700M | -4.37200M | -5.33900M | -10.44300M | -16.38200M |
| Change in cash | -11.24000M | 5.30M | 1.78M | -3.61600M | -11.02600M |
| Begin period cash flow | 16.54M | 11.24M | 9.46M | 13.07M | 24.10M |
| End period cash flow | 5.30M | 16.54M | 11.24M | 9.46M | 13.07M |
| Total cash from operating activities | -9.97500M | -3.22400M | -2.19300M | -4.15200M | -11.55300M |
| Issuance of capital stock | 0.09M | 10.08M | 0.05M | 0.90M | 0.08M |
| Depreciation | 2.71M | 2.58M | 2.68M | 2.64M | 2.65M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | - | - | 40.12M |
| Change to inventory | 1.01M | -0.01900M | -1.25900M | 1.00M | -0.93300M |
| Change to account receivables | -0.86300M | -2.20600M | 2.63M | -2.16000M | -5.99500M |
| Sale purchase of stock | - | - | 0.05M | 0.90M | -0.12200M |
| Other cashflows from financing activities | -0.09800M | -0.04000M | 4.28M | 40.27M | 76.44M |
| Change to netincome | - | -1.04600M | 0.89M | 2.99M | 5.59M |
| Capital expenditures | 0.26M | 0.62M | 0.62M | 0.17M | 0.17M |
| Change receivables | - | - | 2.63M | -2.16000M | -5.99500M |
| Cash flows other operating | - | - | -0.68300M | -0.82800M | 0.13M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | 1.07M | -3.45700M | -10.77800M |
| Change in working capital | 2.69M | -1.34900M | -1.39000M | -0.18100M | -4.24700M |
| Stock based compensation | 0.91M | 1.00M | 1.33M | 2.46M | 4.41M |
| Other non cash items | 1.71M | -1.68900M | 0.50M | 0.92M | 2.67M |
| Free cash flow | -10.23000M | -3.84500M | -2.81300M | -4.32600M | -11.72800M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ALIM Alimera Sciences Inc |
- -% | - | - | 117.65 | 2.28 | 4.00 | 2.95 | -213.5159 |
| ZTS Zoetis Inc |
-1.87 1.53% | 120.49 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
0.56 2.23% | 25.64 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
-2.64 2.02% | 128.01 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.14 0.77% | 18.21 | 32.67 | 11.53 | 0.01 | 0.87 | 0.02 | 0.07 |
Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
6310 Town Square, Alpharetta, GA, United States, 30005
| Name | Title | Year Born |
|---|---|---|
| Mr. Charles Daniel Myers | Non-Exec. Chairman & Consultant | 1954 |
| Mr. Richard S. Eiswirth Jr. | Pres, CEO, Interim CFO & Director | 1968 |
| Mr. David R. Holland | Co-Founder, Chief Marketing Officer and Sr. VP of Corp. Communications & Managed Markets | 1964 |
| Dr. Philip Ashman Ph.D. | COO & Sr. VP of Commercial Operations - Europe | 1965 |
| Christopher S. Visick | VP, Gen. Counsel & Sec. | NA |
| Dr. David Dyer M.D. | Chief Retina Specialist | NA |
| Mr. Richard S. Eiswirth Jr. | CEO & Director | 1968 |
| Mr. David R. Holland | Co-Founder, Chief Marketing Officer and Senior VP of Corporate Communications & Managed Markets | 1964 |
| Dr. Philip Ashman Ph.D. | President of International Operations | 1965 |
| Mr. Todd Michael Wood | President of U.S. Operations | 1970 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...